Drozitumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1][2] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[3][4] Drozitumab was developed by Genentech.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | DR5 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6334H9792N1700O2000S42 |
| Molar mass | 143104.43 g·mol−1 |
  (what is this?) (verify) | |
Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.[3]
